Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member true

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents

Full Query

IC:A61K33/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2020/182927POTASSIUM-BINDING AGENTS FOR USE IN HEMODIALYSIS PATIENTS
WO 17.09.2020
Int.Class A61K 33/24
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
24Heavy metals; Compounds thereof
Appl.No PCT/EP2020/056595 Applicant ASTRAZENECA AB Inventor JONASSON, Jenny
The present invention relates to the use of potassium-binding agents that are formulated to remove toxins, e.g., potassium ions, from the gastrointestinal tract at an elevated rate, without causing undesirable side effects, in hemodialysis patients. The compositions exhibit desired characteristics for the long term administration to treat or prevent the relapse or occurrence of certain conditions, for example hyperkalemia.
2.WO/2020/186057BIOMARKERS FOR JOINT AILMENTS AND USES THEREOF
WO 17.09.2020
Int.Class A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
Appl.No PCT/US2020/022389 Applicant NOVUS INTERNATIONAL INC. Inventor CHEN, Juxing
The present invention relates to biomarkers that are associated with joint disorders, and methods of using the biomarkers diagnose joint ailments, monitor the progression of joint ailments, determine when treatments is indicated, and monitor the efficiency of treatment. Also provided are methods for treating joint ailments, which comprise administering chelated trace minerals to animals diagnosed with or predisposed to having joint ailments.
3.WO/2020/185996METHODS OF TREATING ACUTE CORONARY SYNDROMES
WO 17.09.2020
Int.Class A61K 31/7004
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7004Monosaccharides having only carbon, hydrogen and oxygen atoms
Appl.No PCT/US2020/022250 Applicant TUFTS MEDICAL CENTER, INC. Inventor SELKER, Harry
The invention provides methods for treating and preventing acute coronary syndromes (ACS). The methods involve initiation of the administration of glucose-insulin-potassium (GIK) soon (e.g., within 3 hours) after the onset of ACS symptoms.
4.WO/2020/181335CONCEALMENT OF HYPOMINERALISED LESIONS
WO 17.09.2020
Int.Class A61K 6/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
6Preparations for dentistry
70comprising inorganic additives
71Fillers
76comprising silicon-containing compounds
Appl.No PCT/AU2020/050239 Applicant THE UNIVERSITY OF MELBOURNE Inventor REYNOLDS, Eric Charles
The present invention relates to compositions and uses for reducing the visibility of hypomineralised dental surfaces or subsurfaces, in particular in dental enamel. In one aspect, the invention involves a method of reducing visibility of a hypomineralised dental surface or subsurface, the method comprising (i) contacting the hypomineralised dental surface or subsurface with a liquid composition comprising at least 40% w/v of phosphopeptide (PP)-stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP) at a pH of less than or equal to pH 6; and (ii) subsequently to (i), raising the pH of the liquid composition applied to the hypomineralised dental surface or subsurface to equal to, or greater than, about 9, thereby forming a gel in and/or on the hypomineralised dental surface or subsurface, thereby reducing visibility of a hypomineralised dental surface or subsurface.
5.WO/2020/184345GAS PRODUCT, METHOD FOR PRODUCING SAME AND METHOD FOR PRODUCING MEDICAL INHALATION GAS
WO 17.09.2020
Int.Class A61K 33/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
33Medicinal preparations containing inorganic active ingredients
Appl.No PCT/JP2020/009238 Applicant SUMITOMO SEIKA CHEMICALS CO., LTD. Inventor YAMADA Masaaki
One aspect of the present invention is a gas product which comprises a gas container and a gas composition that is filled into the gas container, and which is configured such that: the gas composition contains nitrogen monoxide, hydrogen and an inert gas; and the concentration of the nitrogen monoxide is 20% by volume or less based on the volume of the gas composition.
6.WO/2020/181334COMPOSITIONS AND METHODS FOR PROMOTING MINERALIZATION
WO 17.09.2020
Int.Class A61K 6/838
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
6Preparations for dentistry
80Preparations for artificial teeth, for filling teeth or for capping teeth
831comprising non-metallic elements or compounds thereof, e.g. carbon
838Phosphorus compounds, e.g. apatite
Appl.No PCT/AU2020/050236 Applicant THE UNIVERSITY OF MELBOURNE Inventor REYNOLDS, Eric Charles
The present invention relates to compositions for uses including mineralizing a dental surface, in particular tooth enamel. Methods of mineralizing hypomineralized lesions (including subsurface lesions) in the tooth enamel caused by various means including dental caries, dental corrosion and fluorosis are also provided. In one aspect, the present invention provides a method of mineralizing a dental surface or sub-surface comprising contacting the dental surface or subsurface with stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP), and simultaneously or subsequently, heating the dental surface or subsurface to which the stabilized ACP and/or ACFP has been, or is being, applied to a temperature greater than 37°C. In another aspect, the present invention provides a method of mineralizing a dental surface or sub-surface comprising contacting the dental surface or subsurface with a liquid composition comprising greater than 20% w/v stabilized amorphous calcium phosphate (ACP) and/or amorphous calcium fluoride phosphate (ACFP).
7.WO/2020/183314PHARMACEUTICAL COMPOSITION CONTAINING PYRROLIDONE CARBOXYLIC ACID AND METALLIC SALT FOR USE IN THE TREATMENT OF HEADACHE
WO 17.09.2020
Int.Class A61K 31/4015
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
4015having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
Appl.No PCT/IB2020/051953 Applicant LABORATORI BALDACCI S.P.A. Inventor BALDACCI, Massimo
The present invention relates to the use of a pharmaceutical composition containing pyrrolidone carboxylic acid (RCA), at least one metal salt, selected from a copper, zinc or manganese salt, and at least one physiologically acceptable excipient, in the treatment of headache, preferably in the treatment of chronic sinusitis headache. Preferably the pharmaceutical composition for use according to the present invention is used in the form of an aerosol, drops or nasal spray.
8.WO/2020/185674A VASOACTIVE TOPICAL COMPOUND TO AFFECT TISSUE BLOOD FLOW, REDUCE TISSUE NECROSIS AND PROMOTE HEALING
WO 17.09.2020
Int.Class A61K 31/5415
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
54having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame
5415ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
Appl.No PCT/US2020/021697 Applicant SOUTH DAKOTA BOARD OF REGENTS Inventor MOYER, Hunter
The present application relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. The present application further relates to methods of making the compositions and using the same.
9.WO/2020/182581COMPOSITION FOR MEASURING MEDICATION COMPLIANCE AND METHOD THEREOF
WO 17.09.2020
Int.Class A61B 5/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
BDIAGNOSIS; SURGERY; IDENTIFICATION
5Measuring for diagnostic purposes; Identification of persons
Appl.No PCT/EP2020/055736 Applicant UNIVERSITE GRENOBLE ALPES Inventor ALCARAZ, Jean-Pierre
The invention relates to the field of medication compliance and more particularly to a composition (10) comprising: - at least one drug substance (13), - at least one detection agent (11), the drug substance (13) being different from the detection agent (11), the composition being configured such that the detection agent (11) makes it possible for the ingestion of the drug substance (13) to be identified. The composition is essentially such that the detection agent (11) comprises at least one hydride (110) able to be dissolved upon contact with an aqueous medium in the human or animal body (2) through the release of dihydrogen. The release of dihydrogen allows the ingestion of the composition (10) to be detected in real time. Moreover, the cost of producing the composition (10) meets the acceptability criteria of the pharmaceutical industry. Thus, the composition (10) is suitable for a very widespread use.
10.WO/2020/184181HYDROGENATION DEVICE AND HYDROGENATION DEVICE STERILIZATION METHOD
WO 17.09.2020
Int.Class A61P 39/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
39General protective or antinoxious agents
06Free radical scavengers or antioxidants
Appl.No PCT/JP2020/007728 Applicant NIHON TRIM CO.,LTD. Inventor NAGI Yuki
A hydrogenation device 1 adds hydrogen to a biocompatible liquid 100 which is sealed in a container 101 having hydrogen molecule permeability. The hydrogenation device 1 comprises: a tank 2 for accommodating the unopened container 101; a hydrogen supply unit 3 for supplying hydrogen into the tank 2; a heating unit 5 for heating a fluid 300 which has accumulated in the tank 2; and a control unit 6 for controlling the heating unit 5 in accordance with whether the container 101 is present in the tank 2.